Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared apixaban (at a dose of 10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months) with conventional therapy (subcutaneous enoxaparin, followed by warfarin) in 5395 patients with acute venous thromboembolism. The primary efficacy outcome was recurrent symptomatic venous thromboembolism or death related to venous thromboembolism. The principal safety outcomes were major bleeding alone and major bleeding plus clinically relevant nonmajor bleeding. RESULTS: The primary efficacy outcome occurred in 59 of 2609 patients (2.3%) in the apixaban group, as compared with 71 of 2635 (2.7%) in the conventional-therapy group (relative risk, 0.84; 95% confidence interval [CI], 0.60 to 1.18; difference in risk [apixaban minus conventional therapy], -0.4 percentage points; 95% CI, -1.3 to 0.4). Apixaban was noninferior to conventional therapy (P<0.001) for predefined upper limits of the 95% confidence intervals for both relative risk (<1.80) and difference in risk (<3.5 percentage points). Major bleeding occurred in 0.6% of patients who received apixaban and in 1.8% of those who received conventional therapy (relative risk, 0.31; 95% CI, 0.17 to 0.55; P<0.001 for superiority). The composite outcome of major bleeding and clinically relevant nonmajor bleeding occurred in 4.3% of the patients in the apixaban group, as compared with 9.7% of those in the conventional-therapy group (relative risk, 0.44; 95% CI, 0.36 to 0.55; P<0.001). Rates of other adverse events were similar in the two groups. CONCLUSIONS: A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding (Funded by Pfizer and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00643201).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Apixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366
Self-citationPulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Farrington, C. P., & Manning, G. (1990) · Statistics in Medicine · doi:10.1002/sim.4780091208 · Cited by 657
Idraparinux versus Standard Therapy for Venous Thromboembolic Disease
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa064247 · Cited by 335
Cited by
Items 201–300 of 1,003
Clinical Evaluation of Factor XIa Inhibitor Drugs
Harrington, J., Piccini, J. P., Alexander, J. H., Granger, C. B., & Patel, M. R. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.057 · Cited by 81
Robertson, L., Kesteven, P., & McCaslin, J. E. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010956.pub2 · Cited by 78
Uresandi, F., Monréal, M., García-Bragado, F., Domenech, P., Lecumberri, R., Escribano, P., Zamorano, J. L., Jiménez, S., Ruiz‐Artacho, P., Lozano, F., et al. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2013.07.008 · Cited by 94
Keita, I., Aubin-Auger, I., Lalanne, C., Aubert, J.-P., Chassany, O., Duracinský, M., & Mahé, I. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s131157 · Cited by 84
3rd GUIDELINE FOR PERIOPERATIVE CARDIOVASCULAR EVALUATION OF THE BRAZILIAN SOCIETY OF CARDIOLOGY
Gualandro, D., Yu, P., Caramelli, B., Marques, A., Calderaro, D., Fornari, L. S., Pinho, C., Feitosa, A. K. N., Polanczyk, C. A., Rochitte, C. E., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170140 · Cited by 90
Ammar, A. A., Ammar, M. A., Owusu, K. A., Brown, S. C., Kaddouh, F., Elsamadicy, A. A., Acosta, J., & Falcone, G. J. (2021) · Neurocritical Care · doi:10.1007/s12028-020-01161-5 · Cited by 79
Prins, M. H., Bamber, L., Cano, S., Wang, M. Y., Erkens, P. M. G., Bauersachs, R. M., & Lensing, A. W. A. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.11.008 · Cited by 80
“In contrast to the trials examining dabigatran, apixaban and edoxaban [25,28–30], which included combined DVT and PE patient populations, the EINSTEIN PE trial of rivaroxaban focused on a specific population of patients with PE (with or without DVT) [31].”
ResultTreatment of Venous Thromboembolism With New Anticoagulant Agents
Becattini, C., & Agnelli, G. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.01.072 · Cited by 82
“Twice-daily apixaban could be preferred for its safety profile, as shown by the 69% reduction in major bleeding (41).”
InfluentialSelf-citationSchein, J. R., White, C. M., Nelson, W. W., Kluger, J., Mearns, E. S., & Coleman, C. I. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0088-y · Cited by 89
Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease
Schafer, J. H., Casey, A. L., Dupre, K. A., & Staubes, B. A. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018781853 · Cited by 83
“Additionally, the Oral Apixaban for the Treatment of Acute Venous Thromboembolism (AMPLIFY) clinical study yielded similar results on bleeding and mortality.(6) Because of these benefits, apixaban has become a popular anticoagulant for these indications.”
ResultGoggs, R. A. N., Blais, M., Brainard, B. M., Chan, D. L., deLaforcade, A. M., Rozanski, E. A., & Sharp, C. R. (2019) · Journal of Veterinary Emergency and Critical Care · doi:10.1111/vec.12801 · Cited by 86
“37 These guidelines are based on a wealth of high-quality evidence resulting from large-scale randomized controlled trials.(38-49) Although some of these guidelines may be applicable to small animals, it is clear that the underlying physiology,(50-53) the overall burden of disease and the most frequently associated di…”
BackgroundManagement dilemmas in acute pulmonary embolism
Condliffe, R. A., Elliot, C. A., Hughes, R. J., Hurdman, J. A., Maclean, R., Sabroe, I., van Veen, J. J., & Kiely, D. G. (2013) · Thorax · doi:10.1136/thoraxjnl-2013-204667 · Cited by 79
Trujillo‐Santos, J., Micco, P. D., Dentali, F., Douketis, J. D., Díaz‐Peromingo, J. A., Núñez, M. J., Cañas, I., Mastroiacovo, D., de Sousa, M. S., Monréal, M., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-07-0494 · Cited by 83
Dawwas, G. K., Leonard, C. E., Lewis, J. D., & Cuker, A. C. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0717 · Cited by 83
Boonyawat, K., Caron, F., Li, A., Chai‐Adisaksopha, C., Lim, W., Iorio, A., Lópes, R. D., Garcia, D. A., & Crowther, M. A. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13701 · Cited by 78
Lutsey, P. L., Walker, R. F., MacLehose, R. F., Alonso, Á., Adam, T. J., & Zakai, N. A. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12222 · Cited by 79
Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants
Enriquez, A. A., Lip, G. Y. H., & Baranchuk, A. M. (2015) · EP Europace · doi:10.1093/europace/euv030 · Cited by 81
“Apixaban and edoxaban were also non-inferior to enoxaparin with significantly less bleeding.(64,65) Reversal strategies of new oral anticoagulants 959”
BackgroundCohen, H., Doré, C. J., Clawson, S., Hunt, B. J., Isenberg, D., Khamashta, M. A., & Muirhead, N. (2015) · Lupus · doi:10.1177/0961203315581207 · Cited by 81
Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
Cirincione, B. B., Kowalski, K. G., Nielsen, J. C., Roy, A., Thanneer, N., Byon, W., Boyd, R. A., Wang, X., Leil, T. A., LaCreta, F. P., et al. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12347 · Cited by 81
Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa
Siegal, D. M., Lu, G., Leeds, J. M., Karbarz, M. J., Castillo, J., Mathur, V. S., Hutchaleelaha, A., Sinha, U., Kitt, M. M., McClure, M. W., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007112 · Cited by 75
“Any AE 13 (54) 4 (50) 27 (75) 15 (83) Gastrointestinal disorders 3 (13) 0 1 (3) 2 (11) General disorders and administration site conditions 6 (25) 2 (25) 5 (14) 4 (22) Infections and infestations 1 (4) 1 (13) 1 (3) 0 Injury, poisoning, and procedural complications 3 (13) 1 (13) 7 (19) 8 (44) Musculoskeletal and connec…”
Sex Differences in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism
Blanco-Molina, Á., Enea, I., Gadelha, T., Tufano, A., Bura-Rivière, A., Micco, P. D., Bounameaux, H., González, J., Villalta, J., & Monréal, M. (2014) · Medicine · doi:10.1097/md.0000000000000114 · Cited by 74
Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin
Bleker, S. M., Hutten, B. A., Timmermans, A., Buller, H. R., Middeldorp, S., Brekelmans, M. P. A., & Scheres, L. J. J. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-11-0874 · Cited by 74
Self-citationCheung, Y. W., Barco, S., Hutten, B. A., Meijers, J. C. M., Middeldorp, S., & Coppens, M. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13115 · Cited by 73
Thrombo-embolic prevention after transcatheter aortic valve implantation
Vranckx, P., Windecker, S., Welsh, R. C., Valgimigli, M., Mehran, R., & Dangas, G. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx390 · Cited by 76
Direct oral anticoagulants: a review on the current role and scope of reversal agents
Chaudhary, R., Sharma, T., Garg, J., Sukhi, A., Bliden, K. P., Tantry, U. S., Turagam, M. K., Lakkireddy, D., & Gurbel, P. A. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01954-2 · Cited by 77
Coons, J. C., Albert, L., Bejjani, A., & Iasella, C. J. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2369 · Cited by 76
Byon, W., Sweeney, K., Frost, C., & Boyd, R. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12184 · Cited by 79
“For intrinsic factors such as age, sex, race, weight, and renal impairment, no dose adjustment or cautionary use of apixaban is recommended, which is supported by subgroup analyses of the pivotal trials that showed maintained benefit–risk profiles of apixaban compared to that of the overall study population.(1,2) Howe…”
BackgroundMethodResultInfluentialPerformance of five different bleeding-prediction scores in patients with acute pulmonary embolism
Klok, F. A., Niemann, C., Dellas, C., Hasenfuss, G. P., Konstantinides, S., & Lankeit, M. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1239-x · Cited by 74
“(i) missing baseline data (ii) PE as an accidental finding obtained during diagnostic workup for another suspected disease, (iii) treatment with thrombolytic drugs or inclusion in the ‘‘Pulmonary Embolism Thrombolysis ‘‘(PEITHO) study [14], (iv) treatment with rivaroxaban or inclusion in the ‘‘Efficacy and Safety Stud…”
MethodEzekowitz, J. A., Lewis, B. S., Lópes, R. D., WOJDYLA, D. M., McMurray, J. J. V., Hanna, M., Atar, D., Bahit, M. C., Keltai, M., Lopez-Sendon, J. L., et al. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvu024 · Cited by 71
Use of direct oral anticoagulants in antiphospholipid syndrome
Cohen, H., Efthymiou, M., & Isenberg, D. A. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14017 · Cited by 73
Hypercoagulation and complement: Connected players in tumor development and metastases
Guglietta, S., & Rescigno, M. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.10.011 · Cited by 73
Chokesuwattanaskul, R., Thongprayoon, C., Tanawuttiwat, T., Kaewput, W., Pachariyanon, P., & Cheungpasitporn, W. (2018) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.13331 · Cited by 74
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Castellucci, L. A., Chen, V. M. Y., Kovacs, M. J., Lazo‐Langner, A., Greenstreet, P., Kahn, S., Côté, B., Schulman, S., de Wit, K., Douketis, J., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2510703 · Cited by 68
The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation
Antonucci, E., Poli, D., Tosetto, A., Pengo, V., Tripodi, A., Magrini, N., Marongiu, F., Palareti, G., & START-Register (2015) · PLoS ONE · doi:10.1371/journal.pone.0124719 · Cited by 71
“Several phase III, non-inferiority, large trials in patients with non-valvular atrial fibrillation (NVAF)[3–6], and studies of acute[7–11]or extended [12,13] treatment in patients with venous thromboembolism (VTE) have recently been published investigating the efficacy and safety of 4 different DOAC (dabigatran, rivar…”
BackgroundCaldeira, D., Barra, M., Ferreira, A., Rocha, A., Augusto, A., Pinto, F. J., Costa, J. N., & Ferreira, J. J. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13412 · Cited by 73
Coagulation and anticoagulation in idiopathic pulmonary fibrosis
Crooks, M. G., & Hart, S. P. (2015) · European Respiratory Review · doi:10.1183/16000617.00008414 · Cited by 75
New oral anticoagulants: a practical guide for physicians
Hinojar, R., Jiménez-Natcher, J. J., Fernández‐Golfín, C., & Zamorano, J. L. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv002 · Cited by 74
Nathan, A. S., Geng, Z., Dayoub, E. J., Khatana, S. A. M., Eberly, L. A., Kobayashi, T., Pugliese, S. C., Adusumalli, S., Giri, J., & Groeneveld, P. W. (2019) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.119.005600 · Cited by 67
Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study)
Nakamura, M., Nishikawa, M., Komuro, I., Kitajima, I., Uetsuka, Y., Yamagami, T., Minamiguchi, H., Yoshimatsu, R., Tanabe, K., Matsuoka, N., et al. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0195 · Cited by 67
Raskob, G. E., Ageno, W., Cohen, A. T., Brekelmans, M. P. A., GROSSO, M. A., Segers, A. E. M., Meyer, G., Verhamme, P. B., Wells, P. S., Lin, M., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00023-5 · Cited by 68
Self-citationRisk stratification and management of acute pulmonary embolism
Becattini, C., & Agnelli, G. (2016) · Hematology · doi:10.1182/asheducation-2016.1.404 · Cited by 78
“55) and this advantage was confirmed in patients included in the study because of pulmonary embolism.(44) In dabigatran studies, 2 safety comparisons were made: from the start of any study drug (from single-dummy period) and from the start of oral drug only (doubledummy period, after warfarin had reached therapeutic l…”
BackgroundSelf-citationSpyropoulos, A. C., Ashton, V., Chen, Y.-W., Wu, B., & Peterson, E. D. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.08.021 · Cited by 70
“This observation of an improved safety profile of DOACs over warfarin has been consistently shown in the pivotal trials [6,29,30].”
BackgroundZhang, Y., Souverein, P. C., Gardarsdóttir, H., van den Ham, H. A., der Zee, A. H. M., & de Boer, A. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14227 · Cited by 74
New oral anticoagulant agents – general features and outcomes in subsets of patients
Schulman, S. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-09-0803 · Cited by 71
“In the studies on treatment of VTE the events were fewer but the differences for intracranial bleeding went in the same direction (14-19).”
BackgroundResultCampello, E., Spiezia, L., Simion, C., Tormene, D., Camporese, G., Valle, F. D., Poretto, A., Bulato, C., Gavasso, S., Radu, C. M., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018917 · Cited by 74
Cohen, A. T., Hamilton, M., Bird, A., Mitchell, S. A., Li, S., Horblyuk, R. V., & Batson, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160064 · Cited by 74
Self-citationThe use of direct oral anticoagulants in inherited thrombophilia
Skelley, J. W., White, C. W., & Thomason, A. R. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1428-2 · Cited by 76
Moudallel, S., Steurbaut, S., Cornu, P., & Dupont, A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01220 · Cited by 65
“According to the pivotal trials, they have a superior safety profile with fewer major bleeding episodes compared to VKAs for both acute as well as extended treatment of patients with VTE (Ezekowitz et al., 2009; Schulman et al., 2009; Landman and Gans, 2011; Agnelli et al., 2013; Hess et al., 2013; Goodman et al., 201…”
BackgroundInfluentialPractical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants
Pollack, C. V., & Weitz, J. I. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-03-0222 · Cited by 70
Self-citationElshafei, M. N., Mohamed, M. F. H., El‐Bardissy, A., Ahmed, M. B., Abdallah, I. M. H., Elewa, H. F., & Danjuma, M. I.-M. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02179-4 · Cited by 72
Johnston, S. (2016) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2015.12.010 · Cited by 73
Fuentes, H. E., Tafur, A. J., & Caprini, J. A. (2016) · Disease-a-Month · doi:10.1016/j.disamonth.2016.03.003 · Cited by 70
Moigne, E. L., Timsit, S., Salem, D. B., Didier, R. J., Jobic, Y., Paleiron, N., Mao, R. L., Joseph, T., Hoffmann, C., Dion, A., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m18-3485 · Cited by 72
Larsen, T. B., Nielsen, P. B., Skjøth, F., Rasmussen, L. H., & Lip, G. Y. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114445 · Cited by 64
“Of the 5 [18–22] RCTs we identified 4 studies that had sufficient data to perform subgroup analyses based on cancer status (no sub-group data available from the AMPLIFY study investigating apixaban [22]).”
BackgroundDirect oral anticoagulants in patients with liver cirrhosis: A systematic review
Hoolwerf, E. W., Kraaijpoel, N., Buller, H. R., & van Es, N. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.08.011 · Cited by 71
Self-citationWang, C., Wu, V. C., Kuo, C., Chu, P., Tseng, H., Wen, M., & Chang, S. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009263 · Cited by 69
Rossel, A., Robert‐Ebadi, H., Combescure, C., Grosgurin, O., Stirnemann, J., Addeo, A., Garin, N., Agoritsas, T., Reny, J., & Marti, C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213940 · Cited by 66
How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy
Schulman, S. (2017) · Blood · doi:10.1182/blood-2017-03-742304 · Cited by 62
Nederpelt, C. J., Naar, L., Krijnen, P., le Cessie, S., Kaafarani, H. M. A., Huisman, M. V., Velmahos, G. C., & Schipper, I. B. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005059 · Cited by 62
Skaistis, J., & Tagami, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137444 · Cited by 64
Long-term outcomes after pulmonary embolism: current knowledge and future research
Kahn, S. R., Houweling, A. H., Granton, J. T., Rudski, L., Dennie, C. J., & Hirsch, A. (2014) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000070 · Cited by 63
Spronk, H. M. H., Padró, T., Siland, J. E., Prochaska, J. H., Winters, J., van der Wal, A. C., Posthuma, J. J., Lowe, G. D. O., D’Alessandro, E., Wenzel, P., et al. (2018) · Thrombosis and Haemostasis · doi:10.1160/th17-07-0492 · Cited by 75
Self-citationGu, Z., Zhou, L., Shen, L., Zhang, C., Pu, J., Lin, H., & Liu, X.-Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00348 · Cited by 64
“1% (4 of 2676) in patients with NOACs (VET trial and 6 months of follow up) (Agnelli et al., 2013).”
BackgroundInfluentialCornell, R. F., Goldhaber, S. Z., Engelhardt, B. G., Moslehi, J. J., Jagasia, M., Harrell, S. L., Rubinstein, S. M., Hall, R. L., Wyatt, H., & Piazza, G. (2020) · British Journal of Haematology · doi:10.1111/bjh.16653 · Cited by 62
“Apixaban was studied as secondary prevention in the randomised AMPLIFY-EXT (Apixaban after Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-Line Therapy–Extended Treatment) trial.(21) In this study, apixaban (2 5 mg or 5 mg twice daily) was evaluated compared to placebo after completion of…”
MethodRezuş, E., Tamba, B.-I., Bădescu, M. C., Popescu, D., Bratoiu, I., & Rezuș, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136801 · Cited by 67
A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease
Parker, K., Hartemink, J., Saha, A., Mitra, R., Lewis, P. J., Power, A. J., Choudhuri, S., Mitra, S., & Thachil, J. V. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01413-x · Cited by 71
“5% in the warfarin arm [18] and rivaroxaban 0.”
BackgroundInfluentialDiagnosis and management of iliofemoral deep vein thrombosis: clinical practice guideline
Liu, D. M., Peterson, E. A., Dooner, J., Baerlocher, M. O., Zypchen, L. N., Gagnon, J., Delorme, M., Sing, C. K., Wong, J., Guzman, R., et al. (2015) · Canadian Medical Association Journal · doi:10.1503/cmaj.141614 · Cited by 68
Beyer‐Westendorf, J., Michalski, F., Tittl, L., Hauswald-Dörschel, S., & Marten, S. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30111-9 · Cited by 61
Goto, S., Haas, S. K., Ageno, W., Goldhaber, S. Z., Turpie, A. G. G., Weitz, J. I., Angchaisuksiri, P., Nielsen, J. D., Kayani, G., Farjat, A. E., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.22886 · Cited by 61
Self-citationSinger, A. J., Thode, H. C., & Peacock, W. F. (2016) · Clinical and Experimental Emergency Medicine · doi:10.15441/ceem.15.096 · Cited by 63
“, rivaroxaban, apixaban, dabigatran, edoxaban).(16-21) Additionally, changes in the healthcare system and financial constraints are leading to a decrease in the number of patients admitted, especially those admitted for short periods.”
BackgroundVenous thromboembolism in the elderly: A narrative review
Tritschler, T., & Aujesky, D. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.05.015 · Cited by 67
Yamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., Toyofuku, M., et al. (2018) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872618799993 · Cited by 67
Pharmacokinetics of new oral anticoagulants: implications for use in routine care
Ingrasciotta, Y., Crisafulli, S., Pizzimenti, V., Marcianò, I., Mancuso, A., Andò, G., Corrao, S., Capranzano, P., & Trifirò, G. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1530213 · Cited by 68
“In detail, findings from RCT reported high adherence (>80%) in around 95% of NOAC users [5,57,60,61], while adherence >80% was reported in 67–88% of patients receiving dabigatran [62-65], 75% of patients treated with rivaroxaban, and 71% treated with apixaban in real-world setting [63].”
BackgroundHill, K. M., Sucha, E., Rhodes, E., Carrier, M., Garg, A. X., Harel, Z., Hundemer, G. L., Clark, E. G., Knoll, G. A., McArthur, E., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.1835 · Cited by 60
Mahé, I., Agnelli, G., Ay, C., Bamias, A., Becattini, C., Carrier, M., Chapelle, C., Cohen, A. T., Girard, P., Huisman, M. V., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1647-9896 · Cited by 62
Self-citationEvaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban
Frost, C. E., Shenker, A., Gandhi, M. D., Pursley, J. M., Barrett, Y. C., Wang, J. J. J., Zhang, D., Byon, W., Boyd, R. A., & LaCreta, F. P. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12393 · Cited by 63
Subramanian, V. B., Katari, N. K., Dongala, T., & Jonnalagadda, S. B. (2019) · Biomedical Chromatography · doi:10.1002/bmc.4719 · Cited by 64
Yaghi, S. R., Saldanha, I. J., Misquith, C., Zaidat, B., Shah, A., Joudi, K., Persaud, B., Khalek, F. A., Shu, L., de Havenon, A., et al. (2022) · Stroke · doi:10.1161/strokeaha.122.039579 · Cited by 58
Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric Population
von Vajna, E., Alam, R., & So, T.-Y. (2016) · Cardiology and Therapy · doi:10.1007/s40119-015-0054-y · Cited by 61
“Most recently, it has been approved for the treatment of DVT and PE and the reduction in the risk of recurrent DVT and PE following initial therapy [38, 39].”
BackgroundGómez-Outes, A., Lecumberri, R., Suárez-Gea, M. L., Terleira-Fernández, A.-I., Monreal, M., & Vargas-Castrillón, E. (2015) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248415575154 · Cited by 57
“10 Case fatality VTE rate (95%CI), % 16 (7-28) 4 (0.”
Haas, S. K., Ageno, W., Angchaisuksiri, P., Bounameaux, H., Nielsen, J. D., Goldhaber, S. Z., Goto, S., Kayani, G., Mantovani, L. G., Prandoni, P., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-04-0335 · Cited by 65
Self-citationOvarian Vein Thrombosis: A Narrative Review
Riva, N., & Calleja‐Agius, J. (2020) · Hämostaseologie · doi:10.1055/a-1306-4327 · Cited by 63
Trends in the Use of Oral Anticoagulants for Adults With Venous Thromboembolism in the US, 2010-2020
Iyer, G. S., Tesfaye, H., Khan, N. F., Zakoul, H., & Bykov, K. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.4059 · Cited by 61
Anticoagulation in Patients with Chronic Kidney Disease
Elenjickal, E. J., Travlos, C. K., Marques, P. S., & Mavrakanas, T. A. (2023) · American Journal of Nephrology · doi:10.1159/000535546 · Cited by 67
Carlin, S., Cuker, A. C., Gatt, A., Gendron, N., Hernández–Gea, V., Meijer, K., Siegal, D. M., Stanworth, S. J., Lisman, T., & Roberts, L. N. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.05.023 · Cited by 67
Antithrombotic Management of Venous Thromboembolism
Renner, E., & Barnes, G. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.07.070 · Cited by 59
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism
Robertson, L., Kesteven, P. J., & McCaslin, J. E. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010957.pub2 · Cited by 62
Mearns, E. S., Kohn, C. G., Song, J.-S., Hawthorne, J., Meng, J., White, C. M., Raut, M. K., Schein, J. R., & Coleman, C. I. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.05.035 · Cited by 61
“1, resulting in 53 total studies included in the analyses [9–61].”
BackgroundBurr, N. E., Lummis, K., Sood, R., Kane, J. S., & Subramanian, V. (2016) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30162-5 · Cited by 60
Direct oral anticoagulant considerations in solid organ transplantation: A review
Salerno, D. M., Tsapepas, D. S., Papachristos, A., Chang, J., Martin, S. T., Hardy, M. A., & McKeen, J. T. (2016) · Clinical Transplantation · doi:10.1111/ctr.12873 · Cited by 55
Overdiagnosis of pulmonary embolism: definition, causes and implications
Dobler, C. C. (2019) · Breathe · doi:10.1183/20734735.0339-2018 · Cited by 65
“apixaban, rivaroxaban) should be considered if anticoagulation is initiated, as novel oral anticoagulants have been found to be non-inferior to conventional therapy for the treatment of acute venous thromboembolism and have a significantly reduced risk of bleeding [40, 41].”
BackgroundAcute treatment of venous thromboembolism
Becattini, C., & Agnelli, G. (2020) · Blood · doi:10.1182/blood.2019001881 · Cited by 64
Self-citationTreatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus
Carrier, M., Blais, N., Crowther, M. A., Kavan, P., Gal, G. L., Moodley, O., Shivakumar, S., Suryanarayan, D., Tagalakis, V., Wu, C. M., et al. (2021) · Current Oncology · doi:10.3390/curroncol28060453 · Cited by 62
Kaneda, K., Yamashita, Y., Morimoto, T., Chatani, R., Nishimoto, Y., Ikeda, N., Kobayashi, Y., Ikeda, S., Kim, K., Inoko, M., et al. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.08.007 · Cited by 58
Planquette, B., Ferré, A., Péron, J., Vial‐Dupuy, A., Pastré, J., Mourin, G., Emmerich, J., Collignon, M., Meyer, G., & Sanchez, O. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.10.030 · Cited by 55
Xu, Y., & Siegal, D. M. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15466 · Cited by 65
Minno, M. N. D. D., Lupoli, R., Minno, A. D., Ambrosino, P., Scalera, A., & Dentali, F. (2015) · Annals of Medicine · doi:10.3109/07853890.2014.982064 · Cited by 56
Portal vein thrombosis: When to treat and how?
Sharma, A., Zhu, D., & Henry, Z. H. (2015) · Vascular Medicine · doi:10.1177/1358863x15611224 · Cited by 55
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review
Bikdeli, B., Tajrishi, F. Z., Sadeghipour, P., Talasaz, A. H., Fanikos, J. R., Lippi, G., Siegal, D. M., Eikelboom, J. W., Monréal, M., Jiménez, D., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.1292 · Cited by 61
Self-citationBertoletti, L., & Humbert, M. J. C. (2015) · La Presse Médicale · doi:10.1016/j.lpm.2015.10.005 · Cited by 53
Metadata
- Authors
- Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., & Weitz, J. I.
- Affiliations
- University of Perugia (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- King's College Hospital (GB)
- Pfizer (United States) (US)
- Flinders University (AU)
- University of Oklahoma Health Sciences Center (US)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08-29
- Volume
- 369
- Issue
- 9
- Pages
- 799-808
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2166402206
- Cited by
- 2,324
- References
- 13
- Citations by year
- 2026: 109 · 2025: 101 · 2024: 134 · 2023: 134 · 2022: 162 · 2021: 193 · 2020: 224 · 2019: 193 · 2018: 213 · 2017: 191 · 2016: 234 · 2015: 198 · 2014: 184 · 2013: 51
- FWCI
- 194.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, acute venous thromboembolism, factor Xa inhibitors, oral anticoagulation, enoxaparin, warfarin, recurrent venous thromboembolism, major bleeding, non-inferiority, fixed-dose regimen, direct oral anticoagulants, anticoagulation duration, venous thromboembolism
- MeSH terms
- Acute Disease, Administration, Oral, Adult, Aged, Anticoagulants, Double-Blind Method, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Warfarin, Treatment Outcome, Enoxaparin, Kaplan-Meier Estimate, Venous Thromboembolism, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.